{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:14:24Z","timestamp":1762899264419},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T00:00:00Z","timestamp":1463702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Gilead Sciences Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12072-016-9726-5","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T10:00:12Z","timestamp":1463738412000},"page":"947-955","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase IIIb study of ledipasvir\/sofosbuvir fixed-dose combination tablet in treatment-na\u00efve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus"],"prefix":"10.1007","volume":"10","author":[{"given":"Young-Suk","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Woon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Young","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly L.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip S.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan-Soo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"key":"9726_CR1","doi-asserted-by":"crossref","unstructured":"Lim YS. Current status of liver disease in Korea: hepatitis C. Korean J Hepatol 2009;15(Suppl 6):S25\u2013S28","DOI":"10.3350\/kjhep.2009.15.S6.S25"},{"key":"9726_CR2","doi-asserted-by":"crossref","unstructured":"Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681\u2013688","DOI":"10.1007\/s00535-013-0770-9"},{"key":"9726_CR3","doi-asserted-by":"crossref","unstructured":"Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107\u2013115","DOI":"10.1111\/j.1469-0691.2010.03432.x"},{"key":"9726_CR4","doi-asserted-by":"crossref","unstructured":"Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586\u2013594","DOI":"10.1111\/liv.12108"},{"key":"9726_CR5","doi-asserted-by":"crossref","unstructured":"Oh DJ, Park YM, Seo YI, Lee JS, Lee JY. Prevalence of hepatitis C virus infections and distribution of hepatitis C virus genotypes among Korean blood donors. Ann Lab Med 2012;32:210\u2013215","DOI":"10.3343\/alm.2012.32.3.210"},{"key":"9726_CR6","doi-asserted-by":"crossref","unstructured":"Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin Mol Hepatol 2012;18:219\u2013224","DOI":"10.3350\/cmh.2012.18.2.219"},{"key":"9726_CR7","doi-asserted-by":"crossref","unstructured":"Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89\u2013136","DOI":"10.3350\/cmh.2014.20.2.89"},{"key":"9726_CR8","doi-asserted-by":"crossref","unstructured":"Park SY, Rim MY, Yo IK, et al. [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis]. Korean J Gastroenterol 2012;60:306\u2013314","DOI":"10.4166\/kjg.2012.60.5.306"},{"key":"9726_CR9","doi-asserted-by":"crossref","unstructured":"Conjeevaram HS, Fried MW, Jeffers LJ, Virahep-C Study Group, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470\u2013477","DOI":"10.1053\/j.gastro.2006.06.008"},{"key":"9726_CR10","doi-asserted-by":"crossref","unstructured":"Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265\u20132271","DOI":"10.1056\/NEJMoa032502"},{"key":"9726_CR11","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958\u2013965","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"9726_CR12","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, PEGASYS International Study Group, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346\u2013355","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"9726_CR13","doi-asserted-by":"crossref","unstructured":"Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 2009;81:2029\u20132035","DOI":"10.1002\/jmv.21583"},{"key":"9726_CR14","doi-asserted-by":"crossref","unstructured":"Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24\u00a0weeks peginterferon alpha-2a (40 kd)\/ribavirin therapy. Hepatology 2006;43:954\u2013960","DOI":"10.1002\/hep.21159"},{"key":"9726_CR15","doi-asserted-by":"crossref","unstructured":"Nicot F, Alric L, Barange K, et al. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol 2011;83:437\u2013444.","DOI":"10.1002\/jmv.21976"},{"key":"9726_CR16","doi-asserted-by":"crossref","unstructured":"Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011;52:363\u2013366","DOI":"10.1016\/j.jcv.2011.08.006"},{"key":"9726_CR17","doi-asserted-by":"crossref","unstructured":"Jung YK, Kim JH, Ahn SM, et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol 2013;47:644\u2013650","DOI":"10.1097\/MCG.0b013e3182896abf"},{"key":"9726_CR18","doi-asserted-by":"crossref","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798\u2013801","DOI":"10.1038\/nature08463"},{"key":"9726_CR19","doi-asserted-by":"crossref","unstructured":"Kim SU, Song KJ, Chang HY, et al. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS ONE 2013;8:e69166","DOI":"10.1371\/journal.pone.0069166"},{"key":"9726_CR20","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975\u2013982","DOI":"10.1056\/NEJMoa020047"},{"key":"9726_CR21","doi-asserted-by":"crossref","unstructured":"H\u00f6roldt B, Haydon G, O\u2019Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int 2006;26:650\u2013659.","DOI":"10.1111\/j.1478-3231.2006.01272.x"},{"key":"9726_CR22","doi-asserted-by":"crossref","unstructured":"Carri\u00f3n JA, Mart\u00ednez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719\u2013728","DOI":"10.1016\/j.jhep.2008.11.015"},{"key":"9726_CR23","doi-asserted-by":"crossref","unstructured":"Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010;201:751\u2013759","DOI":"10.1086\/650470"},{"key":"9726_CR24","doi-asserted-by":"crossref","unstructured":"Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6865 patients 65\u00a0yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260\u20131267","DOI":"10.1111\/j.1572-0241.2006.00556.x"},{"key":"9726_CR25","doi-asserted-by":"crossref","unstructured":"Nudo CG, Wong P, Hilzenrat N, Desch\u00eanes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006;20:589\u2013592","DOI":"10.1155\/2006\/357259"},{"key":"9726_CR26","doi-asserted-by":"crossref","unstructured":"Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1606\u20131612","DOI":"10.1086\/497597"},{"key":"9726_CR27","unstructured":"Gilead Sciences, Inc. HARVONI (ledipasvir and sofosbuvir) prescribing information. Foster City: Gilead Sciences, Inc.; 2014."},{"key":"9726_CR28","unstructured":"Gilead Sciences International Ltd. HARVONI (ledipasvir\/sofosbuvir) summary of product characteristics. Cambridge: Gilead Sciences International Ltd.; 2014"},{"key":"9726_CR29","doi-asserted-by":"crossref","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889\u20131898","DOI":"10.1056\/NEJMoa1402454"},{"key":"9726_CR30","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879\u20131888","DOI":"10.1056\/NEJMoa1402355"},{"key":"9726_CR31","doi-asserted-by":"crossref","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483\u20131493","DOI":"10.1056\/NEJMoa1316366"},{"key":"9726_CR32","doi-asserted-by":"crossref","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645\u2013653","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"9726_CR33","doi-asserted-by":"crossref","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31\u201341","DOI":"10.1159\/000180580"},{"key":"9726_CR34","doi-asserted-by":"crossref","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404\u2013413","DOI":"10.1093\/biomet\/26.4.404"},{"key":"9726_CR35","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Samaniego J, Romero M, Granados R, et al. Factors associated with early virological response to peginterferon-\u03b1-2a\/ribavirin in chronic hepatitis C. World J Gastroenterol 2013;19:1943\u20131952","DOI":"10.3748\/wjg.v19.i12.1943"},{"key":"9726_CR36","doi-asserted-by":"crossref","unstructured":"Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639\u2013644","DOI":"10.1053\/jhep.2003.50350"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9726-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9726-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9726-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9726-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:37:21Z","timestamp":1559446641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9726-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["9726"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9726-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}